Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit.
The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the companies are combining AI reasoning, scientific literature, validated computational engines, and scalable compute within a scientific workflow.
The announcement coincides with NVIDIA’s introduction of the BioNeMo Agent Toolkit at the BIO International Convention.
The integration is initially focused on two areas:
Grounding scientific reasoning in trusted evidence
Composer agents are expected to leverage NVIDIA Nemotron™ Parse to extract and structure information from scientific literature, enabling agents to retrieve relevant evidence while maintaining provenance back to the original source. Researchers can trace recommendations and conclusions to the supporting literature and data.
Accelerating quantitative systems pharmacology at scale
The companies are together advancing nvQSP, a collaborative development initiative focused on CUDA-optimized ordinary differential equation (ODE) solvers for quantitative systems pharmacology (QSP). By accelerating computationally intensive simulations on NVIDIA accelerated computing infrastructure, nvQSP enables scientists to explore larger parameter spaces, evaluate more hypotheses, and iterate more rapidly across complex biological systems. nvQSP builds on the companies’ previously announced work to accelerate computationally intensive QSP workflows using GPU-optimized simulation technology.
These capabilities are being incorporated into Composer, allowing agents to coordinate scientific workflows while remaining rooted in validated computational engines and source-based evidence.
“AI can help scientists explore more possibilities, but in drug development those insights must remain reproducible, explainable, and grounded in validated science,” said Erik Guffrey, Co-Chief Product and Technology Officer of Simulations Plus. “By combining the NVIDIA BioNeMo Agent Toolkit with our scientific engines, we’re building agents that seek to accelerate scientific work while preserving the rigor required for critical development decisions.”
The initiative reflects Simulations Plus’ strategy to connect AI reasoning, scientific knowledge, and validated computational engines within a unified environment for model-informed drug development.
“We believe agentic AI represents an important evolution in how scientists interact with models, data, and scientific knowledge,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Our goal is to help researchers move from question to insight more efficiently while keeping validated science at the center of decision-making.”